Yu Liu

Dr. Yu Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
HLHuan Li
Huan Li
RLRen-Bin Liu
Ren-Bin Liu
CLChen-Meng Long
Chen-Meng Long
YTYuan Teng
Yuan Teng
LCLin Cheng
Lin Cheng
YLYu Liu
Yu Liu
Purpose: Breast cancer (BC) is a multi-factorial disease. Its individual prognosis varies; thus, individualized patient profiling is instrumental to improving BC management and individual outcomes. An economical, multiparametric, and practical model to predict BC recurrence is needed. Patients and Methods: We retrospectively investigated the clinical data of BC patients treated at the Third Affiliated Hospital of Sun Yat-sen University and Liuzhou Women and Children’s Medical Center from January 2013 to December 2020. Random forest-recursive feature elimination (run by R caret package) was used to determine the best variable set, and the random survival forest method was used to develop a predictive model for BC recurrence. Results: The training and validations sets included 623 and 151 patients, respectively. We selected 14 variables, the pathological (TNM) stage, gamma-glutamyl transpeptidase, total cholesterol, Ki-67, lymphocyte count, low-density lipoprotein, age, apolipoprotein B, high-density lipoprotein, globulin, neutrophil count to lymphocyte count ratio, alanine aminotransferase, triglyceride, and albumin to globulin ratio, using random survival forest (RSF)-recursive feature elimination. We developed a recurrence prediction model using RSF. Using area under the receiver operating characteristic curve and Kaplan–Meier survival analyses, the model performance was determined to be accurate. C-indexes were 0.997 and 0.936 for the training and validation sets, respectively. Conclusion: The model could accurately predict BC recurrence. It aids clinicians in identifying high-risk patients and making treatment decisions for Breast cancer patients in China. This new multiparametric RSF model is instrumental for breast cancer recurrence prediction and potentially improves individual outcomes.

29 September 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
ZLZhanyi Li
Zhanyi Li
XLXiangyong Li
Xiangyong Li
XSXiaoqiong Shao
Xiaoqiong Shao
QXQinyao Xu
Qinyao Xu
YWYuankai Wu
Yuankai Wu
YLYu Liu
Yu Liu
Hyperthyroidism complicated by liver failure is associated with high mortality, and the optimal treatment strategy remains unclear. We aimed to compare the clinical characteristics of patients who received different treatments for hyperthyroidism and liver failure. This retrospective cohort study included 137 patients diagnosed with hyperthyroidism and Liver failure between January 2013 and December 2022. The patients were treated with methimazole (MMI) plus artificial liver support system (ALSS), radioactive iodine (131I) plus ALSS, or MMI alone for 24 weeks. Liver and thyroid function were monitored to determine treatment efficacy and potential complications. After propensity score matching, no significant differences in treatment efficacy were observed between MMI plus ALSS and MMI alone at discharge (P = 0.425), 12 weeks (P = 0.104), or 24 weeks (P = 0.104). There were also no significant differences in treatment efficacy between 131I plus ALSS and MMI alone. However, hospital stays were shorter in the MMI and 131I plus ALSS groups than in the MMI alone group (P = 0.014 and P = 0.010, respectively). The incidence of adverse events did not differ significantly between the groups. Our results suggest that 131I plus ALSS, MMI plus ALSS or MMI are effective in treating hyperthyroidism and liver failure, and that the addition of ALSS reduces recovery times. Therefore, clinicians can select any of these treatment options based on specific patient characteristics.

1 March 2025 in Cancer Management and Research
Verified
Journal Article
Open access
ZLZhan-Yi Li
Zhan-Yi Li
YTYuan Teng
Yuan Teng
CLChen-Meng Long
Chen-Meng Long
RLRenbin Liu
Renbin Liu
YLYu Liu
Yu Liu
Special populations are not enrolled in randomized clinical trials, and their safety and efficacy of anticancer therapy are not well described. We aimed to assess the safety and efficacy of anticancer therapy in breast cancer (BC) patients with cirrhosis. We performed a retrospective case-control study (1:5) to assess the adverse events (AEs) morbidity and mortality of anticancer therapy in BC patients with cirrhosis based on a review of patients' medical records. We included 26 BC patients with cirrhosis and 130 matched BC patients without cirrhosis. Postoperative morbidity was higher in the group with cirrhosis (26.9% vs 6.9%, P = 0.007) when postoperative mortality was not significance (3.8% vs 0%, P = 0.167). Liver toxicity (73.1% vs 26.9%, P < 0.001) was more frequent in the group with cirrhosis. The incidence of disruption and mortality during chemotherapy was higher in the group with cirrhosis (46.2% vs 3.1%, P < 0.001 and 15.4% vs 0%, P = 0.001, respectively). The 2-year recurrence rate and 2-year metastasis rate were higher in the group with cirrhosis (19.0% vs 3.8%, P = 0.022 and 23.8% vs 6.9%, P = 0.028). Cirrhosis was the risk factor for liver metastasis (OR: 17.326, 95% CI: 2.164-138.707, P=0.007). It is safe for BC patients with compensated cirrhosis to accept surgery. But they are vulnerable to AEs, disruptions and death during chemotherapy and have poor prognosis. Multidisciplinary cooperation before therapy and closely monitoring AEs during therapy are critical. Attention should be given to optimize the prognosis of special BC patients.

12 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
YTYuan Teng
Yuan Teng
HLHuan Li
Huan Li
LCLin Cheng
Lin Cheng
YJYingming Jiang
Yingming Jiang
HJHua Jiang
Hua Jiang
YLYu Liu
Yu Liu
Background: Triple-negative breast cancer lacks established targeted therapies, and only a subset of patients achieves a pathologic complete response to neoadjuvant chemotherapy. We aimed to integrate bulk cohorts with an exploratory single-cell multi-omic dataset from only five patients to identify tumor and immune-related features associated with chemotherapy response. Methods: Bulk analyses were performed in two public breast cancer cohorts (GSE76275 and GSE25065) to compare triple-negative versus non-triple-negative tumors and to relate pretreatment transcriptional and inferred immune infiltration patterns to neoadjuvant chemotherapy response. Separately, in a hypothesis-generating single-cell cohort of five triple-negative breast cancers (n = 5; four responders, one non-responder), we performed single-cell RNA sequencing, T cell and B cell receptor sequencing, single-cell ATAC sequencing, and glycosylation tag profiling. Results: In bulk data, triple-negative tumors showed a loss of luminal estrogen receptor-associated programs, higher proliferation, and CIBERSORT-estimated enrichment of myeloid-associated immune fractions compared with non-triple-negative tumors. Chemotherapy response was associated with modest transcriptional shifts and inferred immune composition differences in triple-negative tumors and more pronounced epithelial, stromal, and inflamed immune changes in non-triple-negative disease. Single-cell data suggested that responder tumors were enriched for T and natural killer cells, antigen-presenting myeloid cells, expanded and diverse T and B cell clonotypes, and immune-associated glycosylation signals, whereas the non-responder sample was dominated by epithelial and fibroblast compartments with secretory, adhesion, and potential immune evasion programs. Checkpoint-related analyses reflected expression patterns and predicted ligand–receptor communication, nominating TIGIT–NECTIN2 as a candidate axis for further investigation. Conclusions: Integrating public bulk cohorts with exploratory single-cell multi-omics supports a model in which chemotherapy sensitivity in triple-negative breast cancer is linked to inflamed, antigen-presenting microenvironments and adaptable antitumor immunity, whereas resistance is associated with stromal and tumor dominance. These candidate biomarkers and pathways require validation in larger independent cohorts, and clinical translation is premature given the exploratory single-cell cohort.